Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
11 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Tenax Therapeutics, Inc.’s names, not what it holds today.
Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 2 in 2023
Applications published
16
2 of them in 2025
Names they are printed under
4
its own name, a former name, a subsidiary
By yearGrantedApplications published
'97'98'01'12'13'14'15'16'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
TENAX THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
10 publishedOXYGEN BIOTHERAPEUTICS, INC. a former name
US, as the owner printed on each patent
5 publishedSynthetic Blood International, Inc. a former name
US, as the owner printed on each patent
0 publishedPHPrecisionMed, LLC a subsidiary
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Apr 30, 2024 | 11,969,424 | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) | Pharmaceuticals | TENAX THERAPEUTICS, INC. |
| Jul 18, 2023 | 11,701,355 | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) | Pharmaceuticals | TENAX THERAPEUTICS, INC. |
| Mar 21, 2023 | 11,607,412 | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) | Pharmaceuticals | TENAX THERAPEUTICS, INC. |
| Jan 4, 2022 | 11,213,524 | Pharmaceutical compositions for subcutaneous administration of levosimendan | Pharmaceuticals | TENAX THERAPEUTICS, INC. |
| Aug 20, 2013 | 8,513,309 | Perfluorocarbons for use in treating pruritus | Pharmaceuticals | OXYGEN BIOTHERAPEUTICS, INC. |
| Mar 26, 2013 | 8,404,752 | Method of treating traumatic brain injury | Pharmaceuticals | OXYGEN BIOTHERAPEUTICS, INC. |
| Jan 1, 2013 | 8,343,515 | Perfluorocarbon gel formulations | Pharmaceuticals | OXYGEN BIOTHERAPEUTICS, INC. |
| Jan 2, 2001 | 6,167,887 | Selected C-10 perfluorinated hydrocarbons for liquid ventilation and artificial blood | Pharmaceuticals | Synthetic Blood International, Inc. |
| Nov 24, 1998 | 5,840,767 | Perfluorocarbons for biological gas exchange and method | Pharmaceuticals | Synthetic Blood International, Inc. |
| Oct 20, 1998 | 5,824,703 | Method of assisting normal breathing in a mammal having a lung disorder | Pharmaceuticals | Synthetic Blood International, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Feb 27, 2025 | 2025/0064799 | ORAL FORMULATIONS OF LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION | Pharmaceuticals | TENAX THERAPEUTICS, INC. |
| Jan 23, 2025 | 2025/0025460 | USE OF A COMBINATION OF LEVOSIMENDAN AND AN SGLT-2 INHIBITOR TO TREAT HEART FAILURE | Pharmaceuticals | TENAX THERAPEUTICS, INC. |
| Aug 15, 2024 | 2024/0269134 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | Pharmaceuticals | TENAX THERAPEUTICS, INC. |
| Apr 6, 2023 | 2023/0107461 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | Pharmaceuticals | TENAX THERAPEUTICS, INC. · patent 11,701,355 granted from it |
| Mar 31, 2022 | 2022/0096470 | PHARMACEUTICAL COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION OF LEVOSIMENDAN | Pharmaceuticals | TENAX THERAPEUTICS, INC. |
| Dec 23, 2021 | 2021/0393625 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | Pharmaceuticals | TENAX THERAPEUTICS, INC. · patent 11,607,412 granted from it |
| Jun 17, 2021 | 2021/0177840 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | Pharmaceuticals | TENAX THERAPEUTICS, INC. · patent 11,969,424 granted from it |
| May 27, 2021 | 2021/0154193 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION | Pharmaceuticals | PHPrecisionMed, LLC |
| Oct 22, 2020 | 2020/0330463 | Pharmaceutical Compositions for Subcutaneous Administration of Levosimendan | Pharmaceuticals | TENAX THERAPEUTICS, INC. · patent 11,213,524 granted from it |
| Aug 25, 2016 | 2016/0243237 | EMULSIONS OF PERFLUOROCARBONS | Pharmaceuticals | TENAX THERAPEUTICS, INC. |
What it applied for, 2024 to 2025: Pharmaceuticals 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.